Company
ProJenX
A New Approach to Treating ALS
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- projenx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
ProJenX is a clinical-stage biotechnology company with novel, brain-penetrant, targeted therapies to address neurodegenerative diseases, with an initial focus on ALS.
Funding snapshot
- Total raised
- $16MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Grant, $1M2024-06-20
Funding rounds
- Grant
- $1M2024-06-20, Company stated
- Series A
- $15M2023-11-02, Company stated
Products
- Other
- Prosetin
Loading relationship preview